TY - JOUR
T1 - ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use
T2 - A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents
AU - Bhatt, Deepak L.
AU - Scheiman, James
AU - Abraham, Neena S.
AU - Antman, Elliott M.
AU - Chan, Francis K.L.
AU - Furberg, Curt D.
AU - Johnson, David A.
AU - Mahaffey, Kenneth W.
AU - Quigley, Eamonn M.
AU - Harrington, Robert A.
AU - Bates, Eric R.
AU - Bridges, Charles R.
AU - Eisenberg, Mark J.
AU - Ferrari, Victor A.
AU - Hlatky, Mark A.
AU - Kaul, Sanjay
AU - Lindner, Jonathan R.
AU - Moliterno, David J.
AU - Mukherjee, Debabrata
AU - Schofield, Richard S.
AU - Rosenson, Robert S.
AU - Stein, James H.
AU - Weitz, Howard H.
AU - Wesley, Deborah J.
PY - 2008/10/28
Y1 - 2008/10/28
N2 - In appropriate patients, oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of H pylori in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding.
AB - In appropriate patients, oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of H pylori in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding.
KW - AHA Scientific Statements
KW - Antiplatelet therapy
KW - Aspirin
KW - Gastroduodenal ulcer
KW - Gastrointestinal bleeding
KW - Gastrointestinal risk
KW - NSAID
KW - Stents
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=56749183852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56749183852&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.108.191087
DO - 10.1161/CIRCULATIONAHA.108.191087
M3 - Article
C2 - 18836135
AN - SCOPUS:56749183852
SN - 0009-7322
VL - 118
SP - 1894
EP - 1909
JO - Circulation
JF - Circulation
IS - 18
ER -